Pfizer and BioNTech have agreed to supply their COVID-19 vaccine to the World Health Organization co-led COVAX vaccine access scheme, two sources familiar with the deal said, the latest in a series of shots to be included in the project aimed at lower-income countries.
President Joe Biden on Tuesday ordered U.S. states to prioritize COVID-19 vaccinations for teachers to ensure children could return to school quickly and safely, and called for every educator to receive at least one shot by the end of March. Gloria Tso reports.
Health Secretary Matt Hancock said there was “exciting new data” showing the effectiveness of the vaccines.He told a Downing Street press conference the data showed that “a single shot of either the Oxford/AstraZeneca vaccine or of the Pfizer vaccine works against severe infection among the over-70s with a more than 80% reduction in hospitalisations”.
Credit: PA - Press Association STUDIO Duration: 01:00Published
CNN’s Becky Anderson speaks to Moldovan President Maia Sandu as the country becomes the first in Europe to receive the coronavirus vaccine under COVAX, an entity run by a coalition of partners including the World Health Organization. Its mission is to buy coronavirus vaccines in bulk and send them to poorer nations that can’t compete with wealthy countries in securing contracts with the major drug companies.
The World Health Organisation's regional director for Europe, Dr Hans Kluge, reports that new cases of Covid-19 in Europe rose 9% last week to just above one million. This has brought a six-week decline in new cases to an end with more than half of the region seeing increasing numbers of new infections.
Credit: PA - Press Association STUDIO Duration: 00:55Published
New data shows that a single jab of either the Oxford-AstraZeneca or the Pfizer-BioNTech Covid jab reduces the chance of needing hospital treatment by over 80%. Health Secretary Matt Hancock told a Downing Street press conference that "a single shot of either the Oxford/AstraZeneca vaccine or of the Pfizer vaccine works against severe infection among the over-70s with a more than 80% reduction in hospitalisations". He added that the data shows "the protection that you get from catching Covid 35 days after a first jab is even slightly better for the Oxford jab than for Pfizer, albeit both results are clearly very strong."
Report by Thomasl. Like us on Facebook at http://www.facebook.com/itn and follow us on Twitter at http://twitter.com/itn
Initial deliveries of the newly approved Johnson & Johnson COVID-19 vaccine should start on Tuesday, senior Biden administration officials said on Sunday, saying they hoped to boost lagging vaccination rates among minorities. Bryan Wood reports.
A single dose of the Pfizer-BioNTech coronavirus vaccine reduces the risk of asymptomatic infections, helping to stem transmission, research suggests.The UK has approved three coronavirus jabs – Pfizer-BioNTech, AstraZeneca-University of Oxford and Moderna – after studies demonstrated they significantly ward off severe disease.With not everyone able to be immunised, or producing a strong immune response as a result of their vaccination, questions lingered as to whether the jabs prevented the infection itself.Asymptomatic infections are particularly important amid the pandemic, given these individuals do not know to isolate and may unwittingly transmit the coronavirus even when they speak.To learn more, medics from the Cambridge University Hospitals NHS Foundation Trust (CUH) swabbed the site's vaccinated and unvaccinated healthcare workers over two weeks.Results suggest the risk of an asymptomatic infection decreases by four times more than 12 days after a worker received the Pfizer-BioNTech jab.
Following President Biden’s announcement that the US will have enough vaccines for every adult by May, Gavi, The Vaccine Alliance’s CEO, Dr. Seth Berkley, discusses how COVAX aims to deliver 2 billion doses by the end of the year.